D. Turner

发表

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen

M. Jamei, J. Dressman, Rodrigo Cristofoletti, 2020, Pharmaceutics.

Development and applications of a physiologically‐based model of paediatric oral drug absorption

M. Jamei, G. Tucker, T. Johnson, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs

Masoud Jamei, David B. Turner, Sibylle Neuhoff, 2017, The AAPS Journal.

The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2017, Journal of pharmaceutical sciences.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

EVA: A Novel Theoretical Descriptor for QSAR Studies

Peter Willett, David B. Turner, P. Willett, 2002 .

Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: In Vivo Bioavailability and Physiologically Based Pharmacokinetic Modeling.

V. Yardley, J. Masania, Ke Wang, 2021, Molecular pharmaceutics.

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

Andrés Olivares-Morales, Leon Aarons, Aleksandra Galetin, 2013, Pharmaceutical Research.

EVA QSAR: Development of Models with Enhanced Predictivity (EVA_GA)

P. Willett, D. Turner, 2000 .

Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models.

M. Jamei, D. Turner, S. Pathak, 2019, Journal of pharmaceutical sciences.

Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.

N. Patel, M. Jamei, E. Kostewicz, 2017, Molecular pharmaceutics.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.

M. Jamei, L. Aarons, M. Bolger, 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Biopharmaceutic In Vitro In Vivo Extrapolation (IVIV_E) Informed Physiologically-Based Pharmacokinetic Model of Ritonavir Norvir® Tablet Absorption in Humans Under Fasted and Fed State Conditions.

M. Jamei, S. Arora, I. Gardner, 2020, Molecular pharmaceutics.

Peter Willett, David B. Turner, P. Willett, 1997 .

Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools.

M. Corsetti, B. Hens, P. Augustijns, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Population-Based Mechanistic Prediction of Oral Drug Absorption

Sebastian Polak, Masoud Jamei, Amin Rostami-Hodjegan, 2009, The AAPS Journal.

Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents

M. Jamei, D. Turner, V. T. Banala, 2021, Pharmaceutics.

Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state.

J. Dressman, M. Kuentz, R. Holm, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8)

M. Jamei, S. Polak, G. Tucker, 2008 .

A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model

M. Jamei, G. Tucker, K. Rowland-Yeo, 2007 .

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Andreas M. Abend, B. Griffin, Diansong Zhou, 2022, Pharmaceutics.

Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

M. Jamei, Yi Wang, S. Neuhoff, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.

Amitava Mitra, Bart Hens, Bo Liu, 2017, Molecular pharmaceutics.

A Population-based PBPK Model for the Prediction of Time-Variant Bile Salt Disposition within GI Luminal Fluids.

L. Marciani, D. Turner, S. Pathak, 2020, Molecular pharmaceutics.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Martin Bergstrand, Xavier Pepin, Erik Sjögren, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon

D B Turner, A Rostami-Hodjegan, M Jamei, 2017, Biopharmaceutics & drug disposition.

In‐vitro–in‐silico investigation of the negative food effect of zolpidem when administered as immediate‐release tablets

J. Dressman, D. Turner, C. J. Andreas, 2019, The Journal of pharmacy and pharmacology.

A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug–Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates

M. Jamei, I. Gardner, A. Pansari, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. Case example: Naproxen.

Rodrigo Cristofoletti, David B Turner, Nikoletta Fotaki, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.

Sebastian Polak, Masoud Jamei, David B Turner, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.

N. Patel, J. Dressman, M. Kuentz, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The EVA spectral descriptor.

D B Turner, P Willett, P. Willett, 2000, European journal of medicinal chemistry.

Evaluation of the EVA descriptor for QSAR studies: 3. The use of a genetic algorithm to search for models with enhanced predictive properties (EVA_GA)

Peter Willett, David B. Turner, P. Willett, 2000, J. Comput. Aided Mol. Des..

Automatic generation of alignments for 3D QSAR analyses.

N E Jewell, D B Turner, P Willett, 2001, Journal of molecular graphics & modelling.

Current status and future opportunities for incorporation of dissolution data in pbpk modeling for pharmaceutical development and regulatory applications: orbito consortium commentary.

Filippos Kesisoglou, Tycho Heimbach, Xavier Pepin, 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.

M. Jamei, D. Pade, D. Turner, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - Case example dipyridamole.

J. Dressman, S. Arora, Ric Barker, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs

M. Jamei, S. Neuhoff, R. Rose, 2017, The AAPS Journal.

Comment on "In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models".

N. Patel, M. Jamei, S. Polak, 2017, Molecular pharmaceutics.

Peter Willett, Trevor W. Heritage, Claire M. R. Ginn, 1997, J. Chem. Inf. Comput. Sci..

PQRI Workshop Report: Application of IVIVC in Formulation Development

Anthony J. DeStefano, Sandra Suarez-Sharp, Maziar Kakhi, 2014 .

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

D. Tompson, F. Salem, J. Bloomer, 2023, CPT: pharmacometrics & systems pharmacology.

Evaluation of a novel infrared range vibration-based descriptor (EVA) for QSAR studies. 1. General application

Peter Willett, David B. Turner, Allan M. Ferguson, 1997, J. Comput. Aided Mol. Des..

LEVERAGING THE USE OF IN VITRO AND COMPUTATIONAL METHODS TO SUPPORT THE DEVELOPMENT OF ENABLING ORAL DRUG PRODUCTS: AN INPHARMA COMMENTARY.

B. Griffin, M. Kuentz, Cordula Stillhart, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2013, Pharmaceutical Research.

A Mechanistic Model for the Prediction of Equilibrium Blood-to-Plasma Concentration Ratio (B/P) in Human Blood: Basic and Neutral Drugs

M. Jamei, A. Rostami-Hodjegan, D. Turner, 2011 .

Effect of Parameter Variations on the Effectiveness of HQSAR Analyses

Peter Willett, Michael Seel, David B. Turner, 1999 .

Development and Validation of the EVA Descriptor for QSAR Studies

Peter Willett, David B. Turner, Allan M. Ferguson, 1999 .

Peter Willett, David B. Turner, P. Willett, 1995 .

Rapid Quantification of Molecular Diversity for Selective Database Acquisition

Peter Willett, David B. Turner, Simon M. Tyrrell, 1997, J. Chem. Inf. Comput. Sci..

D-LogP: an alignment-free 3D description of local lipophilicity for QSAR studies.

Roger Lahana, David Turner, Jérôme Gomar, 2004, Methods in molecular biology.